Gilead Sciences (GILD)
Develops HIV antivirals, liver-disease medicines, and oncology therapies including CAR-T treatments.
Something off on this page? Send us feedback.
Develops and sells HIV treatment and prevention medicines led by Biktarvy, alongside liver-disease drugs, Trodelvy, and Kite CAR-T therapies. HIV supplies most product revenue, while drug approvals, patent protection, reimbursement, and specialized cell-therapy delivery shape the business.
Develops and commercializes medicines across HIV, liver disease, oncology and COVID-19. The HIV portfolio pairs the single-tablet Biktarvy regimen with Descovy, Sunlenca and twice-yearly Yeztugo for prevention. Liver products include Epclusa, Vemlidy, Hepcludex and Livdelzi, while oncology spans the antibody-drug conjugate Trodelvy and Kite’s Yescarta and Tecartus CAR-T cell therapies.
Markets products in the United States, Europe and other approved regions through wholesale distribution, local commercial teams, partners and specialized cell-therapy operations. Long-acting antiviral development and single-tablet regimen design underpin the HIV franchise; recent acquisitions add investigational cell therapy, antibody-drug conjugate and immune-disease programs. Most product revenue comes from HIV, and commercialization depends on patent exclusivity, regulatory approval, payer reimbursement and concentrated U.S. wholesale channels.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | Reiterate | Rating: —Target: $155 | Target: $175 |
| Aug 5, 2026 | Truist Financial | Target | Target: $157 | Target: $150 |
| Aug 5, 2026 | RBC Capital | Reiterate | Rating: —Target: $120 | Target: $123 |
| Jul 29, 2026 | Barclays | Reiterate | Rating: —Target: $155 | Target: $145 |
| Jul 27, 2026 | Morgan Stanley | Reiterate | Rating: —Target: $166 | Target: $165 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.18B · Total debt $26.25B · Total assets $49.36B · Shareholders' equity $11.83B
- Revenue
- $7.80B
- Operating income
- −$10.39B
- Net income
- −$10.50B
HistoryDividendAnnual yield
| Institutions | 90.32% | 1.12B shares | |
|---|---|---|---|
| 2,370 holders · as of Jun 30, 2026 | |||
| Insiders | 0.10% | 1.19M shares | |
| 17 holders · as of Sep 16, 2026 | |||
| Other | 9.58% | 118.84M shares | |
| remainder | |||
1.24B company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 9.83% | 121.84M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.54% | 81.09M | as of Jun 30, 2026 |
FMR LLCInstitution | 5.39% | 66.87M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.94% | 61.22M | as of Jun 30, 2026 |
Capital World InvestorsInstitution | 3.31% | 40.99M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Andrew D. Dickinson | officer: Chief Financial Officer | −3,000 | $145.29 |
| Sep 15, 2026 | Johanna Mercier | officer: Chief Comm & Corp Aff Officer | −3,000 | $144.22 |
| Sep 1, 2026 | Daniel Patrick O'Day | director, officer: Chairman & CEO | −15,000 | $148.64 |
| Aug 26, 2026 | Anthony Welters | director | −18,000 | $148.62 |
| Aug 20, 2026 | Jeffrey Bluestone | director | −5,000 | $145.02 |
- GSK (ADR)
Second-largest HIV franchise via ViiV; dolutegravir and long-acting injectables
- AstraZeneca (ADR)
Datroway (TROP-2 ADC) and Enhertu contest Trodelvy in breast cancer
- Merck
DOR/ISL HIV filing in 2026; Keytruda overlaps in oncology combos
- Bristol-Myers Squibb
Breyanzi vs Yescarta in lymphoma; Abecma vs anito-cel in myeloma
- Johnson & Johnson
Carvykti BCMA CAR-T leads multiple myeloma, targeted by anito-cel
- Novartis (ADR)
Kymriah, pioneer CD19 CAR-T, competes with Yescarta in lymphoma
- AbbVie
Mavyret holds ~41% HCV share vs Epclusa and Harvoni
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Gilead Sciences | $152.67 | 0.00% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| GSK (ADR) | $50.70 | −0.06% | $102.34B | 16.1 | 9.3 | 2.3 | +5.3% |
| AstraZeneca (ADR) | $168.07 | −0.18% | $260.70B | 25.2 | 15.8 | 4.2 | +6.4% |
| Merck | $151.18 | +0.18% | $369.24B | 119.6 | 17.5 | 5.6 | +5.1% |
| Bristol-Myers Squibb | $62.25 | +0.01% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| Johnson & Johnson | $269.09 | −0.07% | $649.40B | 31.2 | 22.7 | 6.6 | +6.6% |
| Novartis (ADR) | $141.28 | +0.01% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| AbbVie | $265.32 | +0.02% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Median | 25.2 | 15.8 | 4.8 | +5.7% |